Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avila bags $40 million up front in oncology drug pact with Sanofi-Aventis

This article was originally published in Scrip

Executive Summary

Avila Therapeutics is to develop drugs that bind covalently to their targets with Sanofi-Aventis for cancer treatment. The companies will design targeted covalent drugs directed towards six undisclosed tumour signalling proteins. Avila is to receive $40 million in up-front and research support payments and is eligible for milestone payments of up to $154 million for each of the six programmes up to regulatory approval.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts